For Sponsors

Fixed-fee, audit ready RWD in weeks

Fixed-fee, audit-ready RWD in weeks

Set up multimodal registries and non-interventional studies, gather precision data, and engage a vibrant community of patients—delivered faster, at a fraction of CRO costs.

Request a demo

<1%

year over year patient drop-off

60,000+

care centers connected flowing in data from EMRs across the U.S.

1/3

cost of study build and time to first patient visit vs CRO

Disease-specific data for precision medicine

First, we build your study with our no-code platform

Launch siteless or hybrid studies in weeks, not months.

Skip long CRO timelines and custom builds. We set up your study using our customizable workflows and prebuilt templates to help you launch complex studies fast, staying audit-ready from day one.

First, we build your study with our no-code platform

Then, multimodal data linked at the patient-level continuously flows into your study database

EHRs, labs, wearables, site generated and patient-reported data often live in silos. Our platform natively integrates multimodal structured and unstructured data into a unified patient-level record.

Data is quality-controlled, normalized and appended in real-time in the study database.

Then, multimodal data linked at the patient-level continuously flows into your study database

Next, build a long-term dynamic patient community available for studies

Access a fully consented patient community with shared records and strong patient-reported outcomes response rates. We identify eligible patients, manage consent, and sustain follow-up—fueling richer datasets.

Next, build a long-term dynamic patient community available for studies

Result: rich, on-demand, patient-level insights.

Access your real-time multimodal dataset anytime, with no data cuts required, and analyze it using the same advanced tools the FDA uses for regulatory reviews.

Result: rich, on-demand, patient-level insights.

Access your real-time multimodal dataset anytime, with no data cuts required, and analyze it using the same advanced tools the FDA uses for regulatory reviews.

Result: rich, on-demand, patient-level insights.

Access your real-time multimodal dataset anytime, with no data cuts required, and analyze it using the same advanced tools the FDA uses for regulatory reviews.

Trusted by industry leaders

Supporting sponsors, sites, and patients

Simple

Detailed

Embleema

Typical CRO

Pricing model

Low fixed fee

Variable custom pricing

Speed to launch

Less than 6 weeks

6-months+

Patients, sites and investigators

Integrated software suite

Patchwork of third party tools

Platform adaptability

High, configuration-based

Low, additional dev and SOWs

Multimodal data

Natively unified at patient-level

Sitting in fragmented systems

Dedicated support

Multi-channel support for proactive resolution

Call-center with longer wait times

Simple

Detailed

Embleema

Typical CRO

Pricing model

Low fixed fee

Variable custom pricing

Speed to launch

Less than 6 weeks

6-months+

Patients, sites and investigators

Integrated software suite

Patchwork of third party tools

Platform adaptability

High, configuration-based

Low, additional dev and SOWs

Multimodal data

Natively unified at patient-level

Sitting in fragmented systems

Dedicated support

Multi-channel support for proactive resolution

Call-center with longer wait times

Simple

Detailed

Embleema

Typical CRO

Pricing model

Low fixed fee

Variable custom pricing

Speed to launch

Less than 6 weeks

6-months+

Patients, sites and investigators

Integrated software suite

Patchwork of third party tools

Platform adaptability

High, configuration-based

Low, additional dev and SOWs

Multimodal data

Natively unified at patient-level

Sitting in fragmented systems

Dedicated support

Multi-channel support for proactive resolution

Call-center with longer wait times

“The team at Embleema demonstrates extensive and deep domain knowledge as well as provided strategic support for preclinical and regulatory activities. We plan to work with them again in the future.”

Daniel D.

CEO Biotech